Brasília – On November 24, the National Regulatory Agency for Private Health Insurance and Plans (Agência Nacional de Saúde Suplementar – ANS) approved the incorporation of four new technologies into the mandatory coverage list for private health plans. The updates, which take effect on December 1, 2025, include a test for detection of NTRK gene fusions in pediatric cancer, an immunoenzymatic urine test for detection of Histoplasma antigen used in the diagnosis of systemic fungal infection, and expanded use of the immunoprophylactic therapy nirsevimab for the prevention of lower respiratory tract infections associated with respiratory syncytial virus (RSV) in infants. A fourth technology was also incorporated with specific clinical indications defined by the agency.

The decision aims to broaden access to diagnostic and preventive tools for rare or severe conditions, improving early detection of cancers and infections and strengthening protection against serious respiratory illness in children. According to ANS, the incorporation reflects ongoing efforts to align coverage requirements with evolving scientific evidence and epidemiological needs within Brazil’s supplementary health system.

Source: ANS